Floatz logo

Taladegib

Idiopathic Pulmonary Fibrosis

Endeavor Biomedicines, Inc.Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Idiopathic Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
Pirfenidone
Endeavor Biomedicines, Inc.
Phase 4A
N-Acetyl-L-Cysteine
Endeavor Biomedicines, Inc.
Phase 4BBB
Nintedanib
Mannkind Corporation
Phase 4BBB
Nerandomilast
Boehringer Ingelheim
Phase 3BB
hsk44459
Haisco Pharmaceutical Group Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Taladegib is also rated in:

Solid Tumors With PTCH1 Loss-of-function MutationsDormant
CCC
Indicative ·
55 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →